紫外线杀菌照射设备降低养老院呼吸道感染发生率:整群随机交叉试验方案(RESPROTECT)
RESPROTECT 是一项多中心、开放队列、四盲、整群随机交叉试验,在法国 12 家养老院公共区域安装 848 台 UVGI 设备,通过内部滤光片实现盲法,比较设备激活与未激活两个流行季的干预效果。主要结局是严重急性呼吸道感染发生率,旨在评估 UVGI 在真实世界中的临床有效性。
要点
- UVGI 在实验条件下可灭活空气病原体,但缺乏随机临床证据。
- RESPROTECT 采用整群随机交叉设计,以严重 ARI 发生率为主要结局。
- 若有效,UVGI 或成为高风险机构可扩展的感染预防策略。
核心结论
- RESPROTECT 旨在评估养老院公共区域持续使用 UVGI 是否能降低居民严重急性呼吸道感染发生率。
- 该试验将为 UVGI 的临床有效性和环境病原体负荷提供稳健数据。
研究设计与样本
- 多中心、开放队列、四盲、整群随机交叉试验,在法国 Haute-Loire 地区 12 家养老院公共区域安装 848 台 UVGI 设备。
- 所有设备均开启,部分含内部滤光片使 UV 光失活而外观无法区分,中心按 1:1 随机分为两组。
关键数值与推荐
- 主要结局为严重急性呼吸道感染(ARI)发生率。
- 次要结局包括任何级别 ARI 发生率、全因住院或死亡、关注的不良事件(角膜炎和红斑)、抗生素消耗、空气和表面病原体负荷及成本效果。
- 所有分析遵循意向性治疗原则,使用混合效应泊松回归模型,固定效应为期,随机效应为群组、群组-期和个体。
临床怎么用
- 若 UVGI 被证实有效,可能成为高风险机构环境中实用、低维护且可扩展的感染预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultraviolet germicidal irradiation (UVGI) has long been recognized for its ability to inactivate airborne pathogens under experimental conditions. However, despite strong in vitro evidence, randomized clinical evidence of its real-world effectiveness remains lacking. Nursing homes-where respiratory infections are a major cause of morbidity and mortality-represent a highly relevant setting to evaluate the preventive potential of UVGI. The RESPROTECT trial aims to assess whether continuous UVGI use in communal areas of nursing homes reduces the incidence of severe acute respiratory infections (ARIs) among residents. METHODS: RESPROTECT is a multicenter, open cohort, quadruple-blind, cluster-randomized, crossover trial. A total of 848 UVGI devices were installed in communal living areas of 12 nursing homes in the Haute-Loire region, France. All devices are switched on, but some contain internal filters that deactivate UV light while remaining indistinguishable from the outside. Centers were randomized 1:1 into two groups: unfiltered UVGI devices active during period 1 (October 2024-April 2025), then filtered (inactive) during period 2 (October 2025-April 2026), or the reverse sequence. The primary outcome is the incidence of severe ARIs. Secondary outcomes include the incidence of ARIs of any grade, all-cause hospitalization or death, adverse events of interest (keratitis and erythema), antibiotic consumption, airborne and surface pathogen loads, and cost-effectiveness. All analyses will follow the intention-to-treat principle and use mixed-effects Poisson regression models with fixed effects for period and random effects for clusters, cluster-periods and individuals. DISCUSSION: RESPROTECT is one of the first large-scale blinded randomized trials to evaluate the clinical effectiveness of UVGI in preventing respiratory infections among elderly residents in nursing homes. It will complement recent findings from the PETRA trial (JAMA Intern Med 2025) and is designed to provide robust data on both clinical outcomes and environmental contamination. If UVGI proves effective, it could represent a practical, low-maintenance, and scalable infection-prevention strategy for high-risk institutional settings. TRIAL REGISTRATION: French RCB identifier: RECHMIE-22-0003 - 2024-A00199-38. CLINICALTRIALS: gov Identifier: NCT06569160 (Registered on August 21, 2024). https://clinicaltrials.gov/study/NCT06569160 .
引用
- Cornille C, Luneau E, Gabillard D, et al. Efficacy of ultraviolet germicidal irradiation (UVGI) devices to decrease the incidence of respiratory infections in nursing homes: study protocol for a cluster randomized crossover trial (RESPROTECT). Trials. 2026. PMID: 42163326. doi:10.1186/s13063-026-09797-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。